Previous studies have demonstrated T-cell dysfunction in patients with hematologic malignancies [8, 47], and blockade of PD-1 and Tim-3 was able to reverse T-cell exhaustion and restore anticancer immunity [48]. Here, HAVCR2 is linked to hematologic disorder.